LRMR Larimar Therapeutics, Inc.
Healthcare$3.47+0.58%ClosedMarket Cap: $297.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.86
P/S
0.00
EV/EBITDA
-0.71
DCF Value
$1.06
FCF Yield
-44.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-134.1%
ROA
-79.6%
ROIC
-106.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-31.1M | $-29.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-64.0M | $-62.5M | $— | — |
| FY null | $0.00 | NaN% | $-172.5M | $-165.7M | $— | — |
| Q3 null | $0.00 | NaN% | $-49.5M | $-47.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-27.8M | $-26.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-31.2M | $-29.3M | $— | — |
| Q4 null | $0.00 | NaN% | $-31.3M | $-28.8M | $— | — |
| FY null | $0.00 | NaN% | $-90.9M | $-80.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-18.3M | $-15.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-24.6M | $-21.6M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-16.7M | $-14.7M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-14.2M | $-13.0M | $-0.30 | — |